NCT05599412View on ClinicalTrials.gov

Post Marketing Surveillance(PMS) Study of Lorviqua in Korea

RecruitingOBSERVATIONAL
Enrollment

600

Participants

Timeline

Start Date

May 22, 2023

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2028

Conditions
Metastatic ALK+ Non Small Cell Lung Cancer
Interventions
DRUG

Lorviqua

As provided in real world practice

Trial Locations (1)

01037

RECRUITING

Pfizer, Seoul

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05599412 - Post Marketing Surveillance(PMS) Study of Lorviqua in Korea | Biotech Hunter | Biotech Hunter